Researchers from National University Hospital (NUH), National Cancer Institute, Singapore (NCIS), the Yong Loo Lin School of Medicine, National University of Singapore, Duke-NUS Medical School and ...

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to ...

Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.

The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat ...

CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...